New combo tackles tough lymphomas
NCT ID NCT03150329
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and vorinostat (Zolinza)—in people with certain lymphomas that have returned or not responded to treatment. Pembrolizumab helps the immune system attack cancer cells, while vorinostat blocks enzymes that help cancer grow. The study involves 52 participants and aims to find the safest dose and see how well the combination works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and vorinostat (Zolinza)
What this could lead to
If successful, this combination could offer a new treatment option for people with certain lymphomas that have stopped responding to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 52 participants, focused on safety and dosing. The combination may not prove effective or may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States